Olaparib

The Basics

What is Olaparib?

Medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer.

Brand names for Olaparib

Lynparza

How Olaparib is classified

Antineoplastic Agents, Enzyme Inhibitors, Signal Transduction Inhibitors, PARP inhibitors

Olaparib During Pregnancy

Olaparib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Olaparib while pregnant

Based on findings in animals and its mechanism of action [see CLINICAL PHARMACOLOGY], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily (see Data). Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies.

Taking Olaparib While Breastfeeding

What are recommendations for lactation if you're taking Olaparib?

No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.

Maternal / infant drug levels

No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.

Possible effects of Olaparib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Olaparib

None listed